Eikon Therapeutics has raised $381 million from its IPO, at the top end of its expectations, in another sign of a pickup in appetite for new biotech listings on the Nasdaq. The South San Francisco ...

Biotechnology companies going public this week are signaling a resurgence for initial public offerings and venture-capital investment in the sector this year. Biotechs Eikon Therapeutics and ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Use the live Eikon Therapeutics Inc share price chart to monitor the movements of the stock in real-time. Assess key data such as the daily change, high and low prices. A handy EIKN trading volume ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...

Eikon Therapeutics shares were down 6%, at $16.90, in the stock's first day of trade on the Nasdaq Global Select Market. Shares of the clinical-stage biopharmaceutical company began trading midday ...

Feb 5 (Reuters) - Drug developer Eikon Therapeutics , headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...

Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...

Eikon Therapeutics, Inc. (Nasdaq: EIKN), a California-based, late-stage biotechnology company, visits the Nasdaq MarketSite in Times Square. Eikon is led by executive and clinical teams behind the ...

Eikon was founded in 2019 by Chemistry Nobel Prize winner Eric Betzig, along with Xavier Darzacq, Luke Lavis and Robert Tjian, and is developing a pipeline of experimental treatments for cancer.

Shares of Eikon Therapeutics are set to begin trading Thursday after the clinical-stage biopharmaceutical company's upsized initial public offering was priced at the top of expectations. Eikon late ...

Eikon Therapeutics raised an upsized US$381m late Wednesday from its Nasdaq IPO that included participation by Merck, a banker involved in the offering told IFR. The banks were multiple times ...